ArticleAsian Pacific journal of cancer prevention : APJCP2026
A Novel Circulating microRNA Signature Panel as a Prognostic Biomarker for in Patients with Colorectal Cancer.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide, necessitating the development of reliable prognostic biomarkers. Circulating microRNAs (miRs) have emerged as promising, non-invasive biomarkers. This study was designed as a comprehensive evaluation, conducted in two independent stages, to identify circulating miRs capable of providing an accurate prognosis of CRC. SUBJECTS: The study included 225 subjects (150 Egyptian CRC patients and 75 healthy controls). We selected 25 miRs based on recent studies and our previous work and evaluated their expression in the Evaluation Group (65 subjects). The miRs showing significant differential expression were further confirmed in the Validation Group (160 subjects: 110 CRC patients and 50 controls). For all samples, miRNAs were extracted, and their concentration, integrity, and purity were measured using a NanoDrop, followed by cDNA synthesis and qRT-PCR analysis.
resultsThe serum levels of eight miRNAs (Let-7c, miR-21, miR-26a, miR-26b, miR-126, miR-146a, miR-223, and miR-374) were significantly higher in CRC patients and were able to discriminate between CRC patients and healthy controls. The combined analysis of all eight miRNAs showed higher specificity, with an AUC of 0.92 and a specificity of 99.73% for CRC patients. The combination of five miRNAs, which exhibited a greater fold change in CRC patients, achieved an AUC of 0.97 and a specificity of 99.6%. In contrast, the combination of miR-21, miR-26a, and miR-26b demonstrated the highest AUC value of 0.974, with a specificity of 99.27%. Computational analysis revealed that CCND1 and TP53 function dually as efficacy and prognostic biomarkers for CRC, and that these roles are regulated by let-7a-5p. Collectively, the data indicate that this novel miRNA signature panel improves prognostic accuracy compared to individual miRNA analysis and may support enhanced patient screening and personalized treatment strategies in CRC.
conclusionWe established a circulating miRs signature panel for the first time to accurately predict the prognosis of Egyptian CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.